Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2026-01-02 · accession 0001193125-26-003111 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-05 | 2026-01-02 | VKTX | MACARTNEY LAWSON | Dir | A - Grant | $0.00 | +3,150 | 51.1K | +7% | $0 |
| D | 2026-01-05 | 2026-01-02 | VKTX | MACARTNEY LAWSON | Dir | A - Grant | $0.00 | +20.4K | 20.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2026-01-02 | A | A | 3,150 | $0.00 | 51,115 | D | — | — | (F1) Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-01-02 | A | A | 20,400 | $0.00 | 20,400 | D | $35.42 · 2027-01-02 to 2036-01-02 | 20,400 Common Stock |